Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial A Randomized Clinical Trial

被引:20
|
作者
Swisher, Elizabeth M. [1 ,13 ]
Rayes, Nadine [2 ]
Bowen, Deborah [3 ]
Peterson, Christine B. [4 ]
Norquist, Barbara M. [1 ]
Coffin, Tara [3 ]
Gavin, Kathleen [5 ]
Polinsky, Deborah [6 ]
Crase, Jamie [1 ]
Bakkum-Gamez, Jamie N. [7 ]
Blank, Stephanie V. [8 ]
Munsell, Mark F. [4 ]
Nebgen, Denise [2 ]
Fleming, Gini F. [9 ]
Olopade, Olufunmilayo I. [9 ]
Law, Sherman [10 ]
Zhou, Alicia [10 ]
Levine, Douglas A. [11 ,12 ]
D'Andrea, Alan [6 ]
Lu, Karen H. [2 ]
机构
[1] Univ Washington, Dept Obstet & Gynecol, Seattle, WA USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gynecol, Houston, TX USA
[3] Univ Washington, Dept Bioeth & Humanities, Seattle, WA 98185 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA
[5] Minnesota Ovarian Canc Alliance, Minneapolis, MN USA
[6] Dana Farber Canc Inst, Boston, MA USA
[7] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN USA
[8] Icahn Sch Med Mt Sinai, Dept Obstet Gynecol & Reprod Sci, New York, NY USA
[9] Univ Chicago Med, Sect Hematol & Oncol, Chicago, IL USA
[10] Color Hlth, Burlingame, CA USA
[11] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[12] Merck Res Labs, Rahway, NJ USA
[13] Univ Washington, Dept Obstet & Gynecol, 1959 NE Pacific St, POB 356460, Seattle, WA 98195 USA
关键词
IN-PERSON; NONINFERIORITY TRIAL; RISK-ASSESSMENT; FAMILY-HISTORY; TELEPHONE; IMPACT; BREAST; SUSCEPTIBILITY; PERCEPTIONS; PATIENT;
D O I
10.1001/jamaoncol.2023.3748
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IMPORTANCE Requiring personalized genetic counselingmay introduce barriers to cancer risk assessment, but it is unknown whether omitting counseling could increase distress. OBJECTIVE To assess whether omitting pretest and/or posttest genetic counseling would increase distress during remote testing. DESIGN, SETTING, AND PARTICIPANTS Making Genetic Testing Accessible (MAGENTA) was a 4-arm, randomized noninferiority trial testing the effects of individualized pretest and/or posttest genetic counseling on participant distress 3 and 12 months posttest. Participants were recruited via social and traditional media, and enrollment occurred between April 27, 2017, and September 29, 2020. Participants were women aged 30 years or older, English-speaking, US residents, and had access to the internet and a health care professional. Previous cancer genetic testing or counseling was exclusionary. In the family history cohort, participants had a personal or family history of breast or ovarian cancer. In the familial pathogenic variant (PV) cohort, participants reported 1 biological relative with a PV in an actionable cancer susceptibility gene. Data analysis was performed between December 13, 2020, and May 31, 2023. INTERVENTION Participants completed baseline questionnaires, watched an educational video, and were randomized to 1 of 4 arms: the control arm with pretest and/or posttest genetic counseling, or 1 of 3 study arms without pretest and posttest counseling. Genetic counseling was provided by phone appointments and testing was done using home-delivered saliva kits. MAIN OUTCOMES AND MEASURES The primary outcomewas participant distress measured by the Impact of Event Scale 3 months after receiving the results. Secondary outcomes included completion of testing, anxiety, depression, and decisional regret. RESULTS A total of 3839 women (median age, 44 years [range 22-91 years]), most of whom were non-Hispanic White and college educated, were randomized, 3125 in the family history and 714 in the familial PV cohorts. In the primary analysis in the family history cohort, all experimental arms were noninferior for distress at 3 months. There were no statistically significant differences in anxiety, depression, or decisional regret at 3 months. The highest completion rates were seen in the 2 arms without pretest counseling. CONCLUSIONS AND RELEVANCE In the MAGENTA clinical trial, omitting individualized pretest counseling for all participants and posttest counseling for those without PV during remote genetic testing was not inferior with regard to posttest distress, providing an alternative care model for genetic risk assessment.
引用
收藏
页码:1547 / 1555
页数:9
相关论文
共 50 条
  • [41] Genetic Susceptibility Testing and Readiness to Control Weight: Results from a Randomized Controlled Trial
    Meisel, Susanne F.
    Beeken, Rebecca J.
    van Jaarsveld, Cornelia H. M.
    Wardle, Jane
    OBESITY, 2015, 23 (02) : 305 - 312
  • [42] Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision making about treatment-focused genetic testing: a randomized controlled noninferiority trial
    Quinn, Veronica F.
    Meiser, Bettina
    Kirk, Judy
    Tucker, Kathy M.
    Watts, Kaaren J.
    Rahman, Belinda
    Peate, Michelle
    Saunders, Christobel
    Geelhoed, Elizabeth
    Gleeson, Margaret
    Barlow-Stewart, Kristine
    Field, Michael
    Harris, Marion
    Antill, Yoland C.
    Cicciarelli, Linda
    Crowe, Karen
    Bowen, Michael T.
    Mitchell, Gillian
    GENETICS IN MEDICINE, 2017, 19 (04) : 448 - 456
  • [43] REFUSAL TO PARTICIPATE IN A TRIAL OFFERING SKIN CANCER GENETIC TESTING IN PRIMARY CARE
    Hay, Jennifer L.
    ANNALS OF BEHAVIORAL MEDICINE, 2019, 53 : S467 - S467
  • [44] Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial
    Grisham, Christopher
    Peshkin, Beth N.
    Sorgen, Lia
    Isaacs, Claudine
    Ladd, Mary Kathleen
    Jacobs, Aryana
    Binion, Savannah
    Tynan, Mara
    Kuchinsky, Emily
    Friedman, Susan
    Taylor, Kathryn L.
    Graves, Kristi
    O'Neill, Suzanne
    Kim, David
    Schwartz, Marc D.
    PUBLIC HEALTH GENOMICS, 2024, 27 (01) : 100 - 109
  • [45] GENETIC TESTING - A REVOLUTION IN THE MAKING
    GALLIVAN, M
    HOSPITALS, 1986, 60 (04): : 78 - 78
  • [46] The value of pre-symptomatic genetic risk assessment for age-related macular degeneration: the Moran AMD Genetic Testing Assessment (MAGENTA) study—a study protocol for a randomized controlled trial
    Emmanuel K. Addo
    M. Elizabeth Hartnett
    Paul S. Bernstein
    Trials, 24
  • [47] Genetic Testing for Prostate Cancer in Clinical Practice
    Pritchard, Colin C.
    JCO PRECISION ONCOLOGY, 2017, 1
  • [48] Remotely delivered exercise to older rural cancer survivors: a randomized controlled pilot trial
    Nancy M. Gell
    Kim Dittus
    Jacqueline Caefer
    Anita Martin
    Myeongjin Bae
    Kushang V. Patel
    Journal of Cancer Survivorship, 2024, 18 : 596 - 605
  • [49] TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing
    Loeb, Stacy
    Keith, Scott W.
    Cheng, Heather H.
    Leader, Amy E.
    Gross, Laura
    Sanchez Nolasco, Tatiana
    Byrne, Nataliya
    Hartman, Rebecca
    Brown, Lauren H.
    Pieczonka, Christopher Michael
    Gomella, Leonard G.
    Kelly, William Kevin
    Lallas, Costas D.
    Handley, Nathan
    Mille, Patrick Johnston
    Mark, James Ryan
    Brown, Gordon Andrew
    Chopra, Sameer
    Mcclellan, Alexandra
    Wise, David R.
    Hollifield, Lucas
    Giri, Veda N.
    JCO PRECISION ONCOLOGY, 2024, 8
  • [50] Remotely delivered exercise to older rural cancer survivors: a randomized controlled pilot trial
    Gell, Nancy M.
    Dittus, Kim
    Caefer, Jacqueline
    Martin, Anita
    Bae, Myeongjin
    Patel, Kushang, V
    JOURNAL OF CANCER SURVIVORSHIP, 2024, 18 (02) : 596 - 605